BRIEF published on 11/13/2025 at 07:35, 2 months 14 days ago Dermapharm Maintains Stability Amid Portfolio Adjustments Growth And Earnings Branded Pharmaceuticals Dermapharm 2025 Financial Results Portfolio Restructuring
PRESS RELEASE published on 11/13/2025 at 07:30, 2 months 14 days ago Stable earnings despite portfolio adjustment - 2025 guidance confirmed, strong growth in branded pharmaceuticals Dermapharm Holding SE reports stable earnings despite portfolio adjustments in Q3 2025, confirms 2025 guidance and strong growth in branded pharmaceuticals Pharmaceuticals Growth Earnings Dermapharm Holding SE Portfolio Adjustment
BRIEF published on 08/26/2025 at 07:35, 5 months 1 day ago Dermapharm Reports Stable Business in H1 2025 and Q2 EBITDA Growth Financial Results EBITDA Growth Revenue Stability Branded Pharmaceuticals Dermapharm Performance
PRESS RELEASE published on 08/26/2025 at 07:30, 5 months 1 day ago Dermapharm confirms stable business development in H1 2025 and records EBITDA growth in Q2 versus prior-year quarter Dermapharm confirms stable business development in H1 2025 with EBITDA growth in Q2. Full-year guidance for 2025 reiterated. Branded pharmaceuticals main growth driver Revenue Pharmaceuticals EBITDA Growth Dermapharm H1 2025
BRIEF published on 08/12/2025 at 07:35, 5 months 15 days ago Dermapharm Holding SE Continues Growth in Q2 2025 Revenue Forecast EBITDA Growth Branded Pharmaceuticals Dermapharm Q2 2025 Performance
PRESS RELEASE published on 08/12/2025 at 07:30, 5 months 15 days ago Dermapharm Holding SE remains on projected growth trajectory in Q2 2025 Dermapharm Holding SE reports Q2 2025 results in line with expectations. Confirms full-year guidance of EUR 1,160–1,200 million revenue and EUR 322–332 million EBITDA Pharmaceuticals EBITDA Growth Dermapharm Holding SE Full-year Guidance Q2 2025 Results
BRIEF published on 06/26/2025 at 17:48, 7 months 1 day ago Dermapharm Holding SE Approves EUR 0.90 Dividend Per Share Sustainability Dividend AGM Financial Outlook Dermapharm
PRESS RELEASE published on 06/26/2025 at 17:43, 7 months 1 day ago Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.90 per share Dermapharm Holding SE's Annual General Meeting approves divident distribution of EUR 0.90 per share for 2024, confirms 2025 outlook and ratifies Board actions Annual General Meeting Financial Year 2024 Dividend Distribution Dermapharm Holding SE EUR 0.90 Per Share
BRIEF published on 05/15/2025 at 07:35, 8 months 12 days ago Dermapharm Holding SE Meets Q1 2025 Expectations, Reinforces Full-Year Forecast Revenue Growth Full-year Guidance EBITDA Decline Branded Pharmaceuticals Dermapharm Q1 2025
PRESS RELEASE published on 05/15/2025 at 07:30, 8 months 12 days ago Dermapharm Holding SE performs in line with projections in Q1 2025, confirms full-year guidance Dermapharm Holding SE reports Q1 2025 results in line with projections, confirming full-year guidance. Revenue increases by 1.2% year-on-year to EUR 302.4 million Adjusted EBITDA Revenue Growth Dermapharm Holding SE Full-year Guidance Q1 2025 Results
Published on 01/28/2026 at 05:35, 16 minutes ago Banyan Gold Intersects High-Grades and Visible Gold at AurMac, Yukon, Canada
Published on 01/28/2026 at 01:00, 4 hours 51 minutes ago Boron One Announces Increase to Private Placement
Published on 01/27/2026 at 22:15, 7 hours 36 minutes ago Biomind Labs Announces CAD $2.52 Million Private Placement Financing
Published on 01/27/2026 at 20:20, 9 hours 31 minutes ago FutureGen Industries is Unaware of Any Material Change
Published on 01/27/2026 at 20:19, 9 hours 31 minutes ago Aroundtown SA announces successful €750 million perpetual notes issuance and tender offer launch
Published on 01/27/2026 at 20:17, 9 hours 33 minutes ago Aroundtown SA announces successful €750 million perpetual notes issuance and tender offer launch
Published on 01/27/2026 at 19:16, 10 hours 35 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/27/2026 at 18:05, 11 hours 45 minutes ago New indication in children from birth for Guerbet's half-dose GBCA, Elucirem™ (Gadopiclenol) approved by European Commission
Published on 01/27/2026 at 18:00, 11 hours 51 minutes ago GEVELOT S.A.: Weekly declaration of share buybacks – 26/01/2026
Published on 01/27/2026 at 17:45, 12 hours 6 minutes ago Imerys-27-01-2026-information-share-capital-and-voting-rights-as-of-31-December-2025
Published on 01/27/2026 at 14:05, 15 hours 45 minutes ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010167296
Published on 01/27/2026 at 14:01, 15 hours 49 minutes ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010167247
